• Sellas Life Sciences Group Inc. has filed a $154.6 million shelf registration for up to 20,000,000 common shares, signaling future capital raising for its oncology programs.
  • The stock's indicative borrow rate has notably increased to 13.25%, reflecting heightened trading activity and potential short interest.
  • These company-specific developments appear to be driving today's 5.6% price increase.